Biocartis deal shows block buyers taking greater care

Sam Kerr

January 24, 2019 02:15 pm

molecule_microscope_PA_230x150 — MOSCOW, RUSSIA - JANUARY 9, 2017: Conducting a cytogenetic testing at the Center of Molecular Diagnostics (CMD), a part of the Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor). Vyacheslav Prokofyev/TASS | Vyacheslav Prokofyev/Tass/PA Images

ECM bankers have found investors more receptive to blocks than expected so far this year. Nonetheless, buyers have demanded more from sellers before they commit to a deal, a trend in evidence in the €55m share sale in Biocartis on Wednesday night.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Equity ABBs-Block Trades Europe Belgium EMEA

SK

Sam Kerr